Rznomics is developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease based on RNA platform technology called trans-splicing ribozyme. Acknowledged by bio-focused institutions, Rznomics has raised \23.7 billion from series A& B and recently raised \37.2 billion from series C, resulting in a total of \60.9 billion of fundraising. Also, Rznomics received \8 billion for the new drug development research funding from the government.

In 2022 1H, Rznomics’ RZ-001 IND submission for the HCC treatment was approved by MFDS, and the clinical trial for the RZ-001 is currently running. In addition to the RZ-001, Rznomics has competitive and innovative pipelines, such as glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Rznomics is also actively partnering with global companies to discuss collaboration opportunities in co-research, co-development, and licensing.

Rznomics entered global licensing agreement with Eli Lilly for RNA-editing Therapeutics in May 2025, and was listed on KOSDAQ market in Dec 2025.

Rznomics Inc.

Org chart

Teams

Offices